On Monday, in the course of current trade, Shares of Xerox Corp (NYSE:XRX), climbed 3.68%, and is now trading at $11.28.
Xerox, has again retained the top position in worldwide managed print services (MPS), according to the latest market landscape report by analyst research group Quocirca. The 2015 rankings mark Xerox’s sixth successive year as the leader.
Xerox assists companies optimize their printing infrastructure with MPS, and streamlines their communication and business processes to grow revenue, reduce costs and operate more efficiently. Through Xerox managed print services, businesses can outsource print administration and cut costs by as much as 30%.
Xerox Corporation provides business process and document administration solutions worldwide. The company’s Services segment offers various business process outsourcing services, such as customer care, transaction processing, human resources, communication and marketing, and consulting and analytics services, in addition to finance, accounting, and procurement services.
During an Afternoon trade, Shares of Relypsa Inc (NASDAQ:RLYP), dipped -7.33%, and is now trading at $27.69.
Relypsa, stated financial results for the quarter ended June 30, 2015. Net loss for the second quarter 2015 was $39.3 million, or $0.95 per share, contrast to $16.7 million, or $0.51 per share, for the comparable period in 2014.
Cash, cash equivalents and short-term investments totaled $299.0 million at June 30, 2015, contrast to $135.8 million at December 31, 2014. Shares outstanding as of June 30, 2015 were 41.6 million.
Relypsa, Inc., a biopharmaceutical company, focuses on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular, and metabolic diseases in the United States.
Finally, CytRx Corporation (NASDAQ:CYTR), gained 5.05% Monday.
CytRx Corporation, declared the closing of its formerly declared underwritten public offering. The gross proceeds from its sale of 10,465,000 shares of common stock at a public offering price of $2.75 per share, counting 1,365,000 shares sold following the full exercise of the underwriters’ option to purchase additional shares, were about $28.8 million preceding to deducting underwriting discounts and commissions and offering expenses payable by CytRx.
CytRx intends to use the net proceeds of the offering to fund clinical trials of its drug candidate aldoxorubicin and its drug discovery activities and for general corporate purposes, which may comprise pre-commercialization activities regardingaldoxorubicin, working capital, capital expenditures, research and development and other commercial expenditures.
CytRx Corporation operates as a biopharmaceutical research and development company specializing in oncology. The company’s product candidate is aldoxorubicin, which is in Phase III clinical trial as a therapy for patients with soft tissue sarcomas (STS) whose tumors have progressed following treatment with chemotherapy; in Phase IIb clinical trial in small cell lung cancer; in Phase II clinical trial in HIV-related Kaposi’s sarcoma; in Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); in Phase Ib trial in combination with ifosfamide in patients with soft tissue sarcoma; and in Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
